Apremilast monotherapy for palmoplantar pustulosis: Report of three cases
Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none
Maruška Marovt, Pij B Marko
doaj +1 more source
Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review. [PDF]
Background Palmoplantar pustulosis (PPP) is a chronic, relapsing inflammatory dermatosis characterized by recurrent sterile pustules localized to the palms and soles, accompanied by significant pain and psychological burden.
Vimbai Chirindo C +4 more
europepmc +2 more sources
Background: Palmoplantar pustulosis is a rare, debilitating, chronic skin disease involving the hands and feet, and there are limited treatment options. Mechanistic findings suggest that interleukin 1 may be a pathogenic driver.
Suzie Cro +12 more
doaj +1 more source
Recent advances in palmoplantar pustulosis [PDF]
Palmoplantar pustulosis (PPP) is a chronic inflammatory condition where crops of sterile pustules with erythematous keratotic lesions causing bleeding and pain appear on the palms and soles. Recently, the European Rare and Severe Expert Network considered PPP as a variant of pustular psoriasis with or without psoriasis vulgaris.
Brunasso, Alexandra Maria Giovanna +1 more
openaire +2 more sources
Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors. [PDF]
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules, erythema, and scaling on the palms and soles, leading to a significantly reduced quality of life.
Nam KH, Kim YS.
europepmc +2 more sources
Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study. [PDF]
Palmoplantar pustulosis (PPP) is a chronic, debilitating skin disease of the palms and/or soles. We report the efficacy and safety of risankizumab (RZB), an interleukin 23 p19 inhibitor, from the JumPPP study (a phase 3, multicenter, randomized, placebo ...
Okubo Y +11 more
europepmc +2 more sources
Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis [PDF]
BACKGROUND: This review’s goals were to investigate apremilast’s efficacy versus placebo in palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP), and apremilast’s efficacy versus methotrexate in PP.
Spencer, Riley K. +10 more
core +1 more source
Pustulosis palmoplantar: a propósito de un caso [PDF]
Sara de Antonio Feu +2 more
doaj +2 more sources
Th17 cells with regulatory phenotype are the main IL-17F and IL-26 producers in palmoplantar pustulosis. [PDF]
Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disorder marked by erythematous pustules and desquamation on the palms and soles. While IL-17 pathways are implicated in PPP, IL-17 blockers have shown modest efficacy, underscoring the need ...
Do TH +18 more
europepmc +2 more sources
Palmoplantar pustulosis associated with membranous glomerulonephritis
Vishal Thakur +3 more
doaj +3 more sources

